HCPLive Network

Tofacitinib Slows Joint Damage in Rheumatoid Arthritis

 
FRIDAY, Jan. 25 (HealthDay News) -- Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA), according to a study published online Jan. 24 in Arthritis & Rheumatism.

Desiree van der Heijde, M.D., Ph.D., from the Leiden University Medical Center in the Netherlands, and colleagues randomly assigned 797 patients with RA who did not respond to methotrexate to receive tofacitinib or placebo. Patients received 5 or 10 mg tofacitinib twice a day. Patients in the placebo group were switched to 5 or 10 mg tofacitinib after three months if they did not respond, and all remaining placebo patients were switched to tofacitinib after six months.

The researchers found that, at six months, the American College of Rheumatology 20 percent improvement criteria response rates were significantly higher for both tofacitinib groups compared to the placebo group (51.5 percent for 5 mg, 61.8 percent for 10 mg, and 25.3 percent for placebo). The tofacitinib groups had reduced progression of joint erosion and joint space narrowing and a greater percentage of patients with no radiographic progression.

"Data from this 12-month interim analysis demonstrate that tofacitinib inhibits progression of structural damage and improves RA disease activity in patients with RA on methotrexate," van der Heijde and colleagues conclude.

The study was funded by Pfizer; several authors disclosed financial ties to Pfizer.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Magnetic resonance is an effective alternative to biopsy for identifying and quantifying fats in the liver, according to results from a study led by a research team at the University of the Basque Country.
Daily supplements of selenium or vitamin E don't seem to protect against the development of age-related cataracts among men, according to a study published online Sept. 18 in JAMA Ophthalmology.
Workplace flu shots are a good investment, a new survey found. The US Centers for Disease Control and Prevention (CDC) on Sept. 19 urged all health care personnel to get flu vaccinations. The CDC also released the results of a survey of 1,882 health care clinicians meant to determine what factors influenced those who got the shots. Among its findings, when workplaces offered free shots on-site, compliance was 61.6% when the vaccinations were offered for one day only. When they were offered for multiple days, compliance rose to 80.4%. When employers did not offer the shots at all, compliance dropped to 49.0%
Cancer patients burdened by stress and family conflicts before surgery may face a higher risk for complications following their operation, according to a study published in a recent issue of the Journal of Gastrointestinal Surgery.
President Barack Obama escalated the fight against antibiotic-resistant bacteria on Thursday, ordering key federal agencies to pursue a national strategy to deal with the threat.
The US Centers for Disease Control and Prevention have released a Category A recommendation for revised routine pneumococcal vaccination in older adults. The recommendation has been published in the Sept. 19 issue of the CDC's Morbidity and Mortality Weekly Report.
The presence of other health care workers improves hand hygiene adherence, according to a study published in the October issue of Infection Control and Hospital Epidemiology.
More Reading